share_log

Insmed Ranks No. 1 on Science's 2024 Top Biopharma Employers List

Insmed Ranks No. 1 on Science's 2024 Top Biopharma Employers List

Insmed在《科学》2024年度生物制药最佳雇主榜单上排名第一
PR Newswire ·  10/24 16:05

—Insmed Leads Science Top Employers List for Fourth Year in a Row—

Insmed连续四年蝉联科学顶级雇主榜首

BRIDGEWATER, N.J., Oct. 24, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it has earned the highest ranking in Science's 2024 Top Employers Survey. The annual survey polls employees in biotechnology, pharmaceutical, and related industries to determine the 20 best employers, as well as their driving characteristics.

2024年10月24日,美国新泽西州布里奇沃特/美通社 – 纳斯达克上市公司Insmed Incorporated(纳斯达克股票代码:INSM)是一家以人为本的全球生物制药公司,致力于提供首选和最佳疗法,改变面临严重疾病患者的生活。今天宣布,该公司在《科学》杂志的2024年度顶级雇主调查中荣获最高排名。该年度调查对生物技术、制药及相关行业的员工进行调查,以确定20家最佳雇主及其核心特质。

"It is a tremendous honor to have been named the No. 1 employer in Science's annual survey for the fourth consecutive year," said Will Lewis, Chair and Chief Executive Officer of Insmed. "This past year has been transformational for our company, as we've demonstrated the strength of our commercial and pipeline programs, continued to fuel the innovation engine behind our early-stage research, and enhanced our culture while growing to more than 1,200 employees around the world. Looking to the future, I am filled with pride and excitement as I think about the talent, dedication, and potential of our team as we strive to make a real difference in the lives of patients with serious diseases."

Insmed董事兼首席执行官Will Lewis表示:“连续第四年被评为《科学》杂志年度调查中的第一名,对我们而言是一项巨大荣誉。过去一年对我们公司来说是变革性的,我们展示了商业和管道计划的实力,继续推动我们早期研究创新引擎,并在全球范围内扩展了我们的团队规模至1200多名员工,同时增强了我们的文化。展望未来,想到我们的团队的才能、奉献精神和潜力,让我充满自豪和期待,因为我们致力于在严重疾病患者的生活中真正产生影响。”

The 2024 survey results were based on nearly 6,500 responses from individuals located primarily across North America (65%), Europe (19%), and Asia/Pacific Rim (11%). This year's highest-ranking companies stood out in the areas of innovative leadership, respect for employees, social responsibility, employee loyalty, and personal and professional value alignment.

2024年调查结果基于近6500份来自主要位于北美(65%)、欧洲(19%)和亚太地区(11%)的个人回应。今年排名最高的公司在创新领导力、对员工的尊重、社会责任、员工忠诚度以及个人和专业价值观一致性方面脱颖而出。

"The culture we've built at Insmed is unlike any other I've experienced, and I am proud to see it continue to grow and strengthen as we expand our global team," said Nicole Schaeffer, Chief People Strategy Officer of Insmed. "Thank you to our colleagues around the world who show up every day with a desire to help patients, enrich our communities, and support one another. It is because of you that we have once again been recognized by Science as the top employer in the biopharma industry."

Insmed首席人才战略官Nicole Schaeffer表示:“我们在Insmed建立的企业文化与我经历过的任何其他文化都不同,我为看到它不断增长和加强,随着我们扩大全球团队而感到自豁。感谢我们全球各地的同事,每天都怀着帮助患者、丰富社区和相互支持的愿望而过。正是因为你们,我们再次被《科学》杂志认定为生物制药行业的顶级雇主。”

The complete feature and company rankings can be accessed here. To learn more about Insmed's culture and explore opportunities to join our team, please visit .

完整功能和公司排名可在此处访问。要了解更多关于insmed文化的信息,并探索加入我们团队的机会,请访问。

About Insmed

关于Insmed

Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company's early-stage research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.

insmed公司是一家以人为本的全球生物制药公司,致力于提供一流和最佳疗法,改变患有严重疾病的患者的生活。该公司正在推进一系列已获批和中后期研究的药物以及聚焦于为需求最大的患者群体提供服务的尖端药物发现。insmed最先进的项目涉及肺部和炎症疾病,包括在美国、欧洲和日本获批用于治疗慢性、令人衰弱的肺部疾病的一种治疗方法。该公司的早期研究项目涵盖各种技术和模式,包括基因疗法、AI驱动的蛋白工程、蛋白质制造、RNA端连接和合成拯救。

Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending four consecutive years as the No. 1 Science Top Employer. Visit to learn more.

总部位于新泽西州布里奇沃特,insmed在美国、欧洲和日本各地设有办公室和研究场所。insmed自豪地成为生物制药行业最佳雇主之一,包括连续四年获得科学顶级雇主第一的荣誉。访问,以了解更多。

Contact:

联系方式:

Investors:

投资者:

Bryan Dunn
Executive Director, Investor Relations
Insmed
(646) 812-4030
[email protected]

Bryan Dunn
执行董事,投资者关系
Insmed
(646) 812-4030
[email protected]

Media:

媒体:

Mandy Fahey
Vice President, Corporate Communications
Insmed
(732) 718-3621
[email protected]

Mandy Fahey
企业通信副总裁
Insmed
(732) 718-3621
[email protected]

SOURCE Insmed Incorporated

Insmed Incorporated

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

想要您公司的新闻在PRNEWSWIRE.COM上特色呈现吗?

440k+
440k+

Newsrooms &
新闻发布室&

Influencers
影响力人士
9k+
9k+

Digital Media
数字媒体

Outlets
Outlets
270k+
270k+

Journalists
新闻记者

Opted In
Opted In
GET STARTED
开始使用
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发